摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Octahydro-cyclopentapyran | 90112-27-9

中文名称
——
中文别名
——
英文名称
Octahydro-cyclopentapyran
英文别名
octahydro-cyclopenta[c]pyran;Octahydrocyclopenta[c]pyran;1,3,4,4a,5,6,7,7a-octahydrocyclopenta[c]pyran
Octahydro-cyclopenta<c>pyran化学式
CAS
90112-27-9
化学式
C8H14O
mdl
——
分子量
126.199
InChiKey
NDNVVBZJAUDNAX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    9.2
  • 氢给体数:
    0
  • 氢受体数:
    1

文献信息

  • [EN] IMIDAZOPYRIDIN-2-ONE DERIVATIVES<br/>[FR] DÉRIVÉS D'IMIDAZOPYRIDIN-2-ONE
    申请人:MERCK SHARP & DOHME
    公开号:WO2012174199A1
    公开(公告)日:2012-12-20
    The present invention is directed to imidazopyridin-2-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    本发明涉及咪唑吡啶-2-酮衍生物,这些衍生物是代谢型谷酸受体的增效剂,特别是mGluR2受体,并且在治疗或预防与谷酸功能障碍相关的神经和精神疾病以及代谢型谷酸受体参与的疾病方面具有用途。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗代谢型谷酸受体参与的这类疾病中使用这些化合物和组合物。
  • Fluorine-Containing Sulfonic Acid Salt, Fluorine-Containing Sulfonic Acid Salt Resin, Resist Composition, and Pattern Forming Method Using Same
    申请人:Central Glass Company, Limited
    公开号:US20150198879A1
    公开(公告)日:2015-07-16
    Disclosed is a fluorine-containing sulfonic acid salt resin having a repeating unit represented by the following general formula (3). In the formula, each A independently represents a hydrogen atom, a fluorine atom or a trifluoromethyl group, and n represents an integer of 1-10. W represents a bivalent linking group, R 01 represents a hydrogen atom or a monovalent organic group, and M + represents a monovalent cation. A resist composition containing this resin is further superior in sensitivity, resolution and reproducibility of mask pattern and is capable of forming a pattern with a low LER.
    本公开了一种含氟磺酸树脂,其具有以下通用式(3)所代表的重复单元。在该式中,每个A独立地表示氢原子、原子或三甲基基团,n表示1-10的整数。W表示二价连接基团,R01表示氢原子或一价有机基团,M+表示一价阳离子。含有该树脂的抗蚀组合物在感光性、分辨率和掩膜图案的重现性方面更加优越,并且能够形成具有较低LER的图案。
  • [EN] MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE<br/>[FR] MONOBACTAMES ET PROCÉDÉS DE SYNTHÈSE ET D'UTILISATION DE CES DERNIERS
    申请人:HARVARD COLLEGE
    公开号:WO2015103583A1
    公开(公告)日:2015-07-09
    Described herein are monobactam antibiotics of Formula (I), (Ι'), (II), and (II'), along with methods and intermediates for preparing these compounds. Pharmaceutical compositions and methods of treating infectious diseases using the monobactams are also provided.
    本文描述了单环内酰胺抗生素的化学式(I)、(Ι')、(II)和(II'),以及制备这些化合物的方法和中间体。还提供了使用单环内酰胺治疗传染病的药物组合物和方法。
  • Chemokine receptor binding heterocyclic compounds
    申请人:Bridger J. Gary
    公开号:US20060264434A1
    公开(公告)日:2006-11-23
    This invention relates to a novel class of heterocyclic compounds that bind chemokine receptors, inhibiting the binding of their natural ligands thereby. These compounds result in protective effects against infection by HIV through binding to chemokine receptors, including CXCR4 and CCR5, thus inhibiting the subsequent binding by these chemokines. The present invention provides a compound of Formula I wherein, W is a nitrogen atom and Y is absent or, W is a carbon atom and Y=H; R 1 to R 7 may be the same or different and are independently selected from hydrogen or straight, branched or cyclic C 1-6 alkyl; R 8 is a substituted heterocyclic group or a substituted aromatic group Ar is an aromatic or heteroaromatic ring each optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups; n and n′ are independently, 0-2; X is a group of the formula: Wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6-membered ring, and P is an optionally substituted carbon atom, an optionally substituted nitrogen atom, sulfur or oxygen atom. Ring B is an optionally substituted 5 to 7-membered ring. Ring A and Ring B in the above formula can be connected to the group W from any position via the group V, wherein V is a chemical bond, a (CH 2 ) n″ group (where n″=0-2) or a C═O group. Z is, (1) a hydrogen atom, (2) an optionally substituted C 1-6 alkyl group, (3) a C 0-6 alkyl group substituted with an optionally substituted aromatic or heterocyclic group, (4) an optionally substituted C 0-6 alkylamino or C 3-7 cycloalkylamino group, (5) an optionally substituted carbonyl group or sulfonyl. These compounds further include any pharmaceutically acceptable acid addition salts and metal complexes thereof and any stereoisomeric forms and mixtures of stereoisomeric forms thereof.
    本发明涉及一种新型杂环化合物类,它们能够结合趋化因子受体,从而抑制它们天然配体的结合。这些化合物通过结合趋化因子受体(包括CXCR4和CCR5),从而抑制这些趋化因子的后续结合,从而产生对HIV感染的保护作用。本发明提供了一种式I的化合物,其中,W是氮原子,Y不存在或W是碳原子且Y=H;R1到R7可以相同也可以不同,且独立地选择氢或直链、支链或环状的C1-6烷基;R8是取代的杂环基或取代的芳香基,Ar是一个芳香或杂芳环,每个环可以在单个或多个非连接位置上选择电子给体或吸引基进行取代;n和n'是独立的0-2;X是下式的基团:其中,环A是可选的取代的饱和或不饱和的5或6元环,P是可选的取代的碳原子、可选的取代的氮原子、或氧原子。环B是可选的取代的5至7元环。上述式中的环A和环B可以通过基团V从任何位置连接到基团W,其中V是一个化学键、一个(CH2)n''基团(其中n''=0-2)或一个C═O基团。Z是(1)氢原子,(2)可选的取代的C1-6烷基,(3)取代的C0-6烷基,其被取代为可选的芳香或杂环基,(4)可选的取代的C0-6烷基基或C3-7环烷基基基团,(5)可选的取代的羰基或磺酰基。这些化合物还包括任何药用可接受的酸盐和属配合物以及任何立体异构体和立体异构体混合物。
  • IMIDAZOPYRIDIN-2-ONE DERIVATIVES
    申请人:Merck Sharp & Dohme Corp.
    公开号:EP2721029A1
    公开(公告)日:2014-04-23
查看更多

同类化合物

(3S,4R)-3-氟四氢-2H-吡喃-4-胺 鲁比前列素中间体 顺式-3-溴<2-(2)H>四氢吡喃 顺-4-氨基四氢吡喃-3-醇 顺-4-(四氢吡喃-2-氧)-2-丁烯-1-醇 顺-3-Boc-氨基-四氢吡喃-4-羧酸 锡烷,三丁基[3-[(四氢-2H-吡喃-2-基)氧代]-1-炔丙基]- 螺[金刚烷-2,2'-四氢吡喃]-4'-醇 蒿甲醚四氢呋喃乙酸酯 蒜味伞醇B 蒜味伞醇A 茉莉吡喃 苯基2,4-二氯-5-氨磺酰苯磺酸酯 苄基2,3-二-O-乙酰基-4-脱氧-4-C-硝基亚甲基-β-D-阿拉伯吡喃果糖苷 膜质菊内酯 红没药醇氧化物A 红没药醇氧化物 科立内酯 硅烷,(1,1-二甲基乙基)二甲基[[4-[(四氢-2H-吡喃-2-基)氧代]-5-壬炔基]氧代]- 甲磺酸酯-四聚乙二醇-四氢吡喃醚 甲基[(噁烷-3-基)甲基]胺 甲基6-氧杂双环[3.1.0]己烷-2-羧酸酯 甲基4-脱氧吡喃己糖苷 甲基3-脱氧-3-硝基-beta-L-核吡喃糖苷 甲基2,4,6-三脱氧-2,4-二-C-甲基吡喃葡己糖苷 甲基1,2-环戊烯环氧物 甲基-[2-吡咯烷-1-基-1-(四氢-吡喃-4-基)-乙基]-胺 甲基-(四氢吡喃-4-甲基)胺 甲基-(四氢吡喃-2-甲基)胺盐酸盐 甲基-(四氢吡喃-2-甲基)胺 甲基-(四氢-吡喃-3-基-胺 甲基-(四氢-吡喃-3-基)-胺盐酸盐 甲基-(4-吡咯烷-1-甲基四氢吡喃-4-基)-胺 甲基(5R)-3,4-二脱氧-4-氟-5-甲基-alpha-D-赤式-吡喃戊糖苷 环氧乙烷-2-醇乙酸酯 环己酮,6-[(丁基硫代)亚甲基]-2,2-二甲基-3-[(四氢-2H-吡喃-2-基)氧代]-,(3S)- 环丙基-(四氢-吡喃-4-基)-胺 玫瑰醚 独一味素B 溴-六聚乙二醇-四氢吡喃醚 氯菊素 氯丹环氧化物 氨甲酸,[[(四氢-2H-吡喃-2-基)氧代]甲基]-,乙基酯 氨甲酸,[(4-氨基四氢-2H-吡喃-4-基)甲基]-,1,1-二甲基乙基酯(9CI) 氧杂-3-碳酰肼 氧化氯丹 正-(四氢-4-苯基-2h-吡喃-4-基)乙酰胺 次甲霉素 A 桉叶油醇